Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteNo recent work listed

Osamu Ishikawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7655-0610; OpenAlex author ID A5030622546. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2011: 4 papers · 2012: 3 papers · 2013: 3 papers · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers

Papers 23

  1. Pathological Nodal and Vascular Involvement Significantly Impacts the Recurrence Risk in Different Time Frames in Patients With Resectable and Borderline Resec… Last author DOI 10.1097/sla.0000000000005879↗
  2. DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1186/s12885-023-10512-2↗
  3. Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreat… Co-author DOI 10.1186/s40792-022-01529-z↗
  4. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradia… Last author DOI 10.1016/j.pan.2020.05.020↗
  5. Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revis… Last author DOI 10.1002/ags3.12288↗
  6. Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk f… Last author DOI 10.1016/j.surg.2018.06.047↗
  7. Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001140↗
  8. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2017.03.015↗
  9. Risk factors for vertebral compression fractures in preoperative chemoradiotherapy with gemcitabine for pancreatic cancer. Last author DOI 10.1016/j.radonc.2016.01.006↗
  10. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical… Last author DOI 10.1097/sla.0000000000001547↗
  11. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Last author DOI 10.1016/j.radonc.2015.01.004↗
  12. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on opera… Last author DOI 10.1016/j.surg.2014.09.022↗
  13. Reply to Letter: "Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer". First author DOI 10.1097/sla.0000000000000684↗
  14. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy … Last author DOI 10.1007/s00268-012-1775-x↗
  15. Risk of peritoneal carcinomatosis by endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Co-author DOI 10.1007/s00535-012-0693-x↗
  16. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Last author DOI 10.1097/sla.0b013e31829b3ce4↗
  17. Pancreaticoduodenectomy for invasive pancreatic cancer (with video). Last author DOI 10.1007/s00534-011-0467-5↗
  18. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including g… Co-author DOI 10.1007/s00534-012-0514-x↗
  19. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based che… Co-author DOI 10.1097/sla.0b013e31823d813c↗
  20. C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage. Co-author DOI 10.1002/gcc.20828↗
  21. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Last author DOI 10.1016/j.surg.2011.03.001↗
  22. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Co-author DOI 10.1038/onc.2011.59↗
  23. [Neoadjuvant chemoradiation for the pancreatic cancer]. Last author PMID 21971139↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hidenori Takahashi · 20 shared papers, 2011–2023 · strength 1.28
  2. Hiroaki Ohigashi · 15 shared papers, 2011–2023 · strength 0.75
  3. Hirofumi Akita · 9 shared papers, 2011–2023 · strength 0.74
  4. Masato Sakon · 7 shared papers, 2015–2023 · strength 0.63
  5. Masahiko Yano · 10 shared papers, 2011–2020 · strength 0.51
  6. Shinichiro Hasegawa · 3 shared papers, 2019–2023 · strength 0.31
  7. Daisaku Yamada · 3 shared papers, 2019–2023 · strength 0.31
  8. Hidetoshi Eguchi · 4 shared papers, 2011–2023 · strength 0.27
  9. Hiroshi Wada · 1 shared paper, 2023 · strength 0.19
  10. Yasuhiko Tomita · 5 shared papers, 2011–2015 · strength 0.17
  11. Kunihito Gotoh · 5 shared papers, 2011–2015 · strength 0.16
  12. Tatsuya Ioka · 3 shared papers, 2013–2018 · strength 0.15
  13. Mitsuru Kinoshita · 1 shared paper, 2022 · strength 0.14
  14. Hiroshi Oka · 1 shared paper, 2022 · strength 0.14
  15. Yosuke Mukai · 1 shared paper, 2023 · strength 0.13
  16. Manabu Mikamori · 1 shared paper, 2023 · strength 0.13
  17. Teruki Teshima · 2 shared papers, 2015–2016 · strength 0.10
  18. Keisuke Otani · 2 shared papers, 2015–2016 · strength 0.10
  19. Koji Konishi · 2 shared papers, 2015–2016 · strength 0.10
  20. Shigeru Marubashi · 3 shared papers, 2011–2015 · strength 0.10
  21. Kazuhiro Katayama · 2 shared papers, 2012–2013 · strength 0.06
  22. Shigenori Nagata · 2 shared papers, 2012 · strength 0.06
  23. Yasuhiro Fujiwara · 1 shared paper, 2017 · strength 0.06
  24. Satoaki Nakamura · 2 shared papers, 2011–2012 · strength 0.05
  25. Yuichiro Doki · 2 shared papers, 2011–2012 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.